From SLCImmuno on licensing deals:
Quote:slcimmuno Member Level Saturday, 07/15/17 07:21:42 PM
Re: None
Post # of 190521
Some good data on Big Rx historic Deal / Licensing activity
https://pharmastore.informa.com/wp-content/up...dacted.pdf
Also, worth noting even the Big Guys do open-label proof of concept trials -- e.g. Celgene N=40 for Mongersen in UC, Endoscopy as a secondary.
https://clinicaltrials.gov/ct2/show/NCT026013...amp;rank=1
And this drug went for $2.7bn with some now way downsizing forecast (if it even gets approved... less than 50/50 imo) sales to $80m.
"Analyst Dane Leone indicated that his mongersen revenue forecast for 2020 is $80 million compared to his previous estimate of $468 million and the consensus forecast of $432 million."
http://m.benzinga.com/article/9677456
Think Prurisol, like others have noted, obv has the potential to move the dial most, tick-tock, but Ipix's PoC UP/UPS ought to draw interest too. Likes of Pfizer, JNJ, Takeda and Celgene Big in IBD space.
Why not put some earnest $ ($50-100m upfront) toward Brilacidin that, in humans, put up some impressive #s and pics showing Remission?